Clinical Trials
28 trialsUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
CART-38 in Adult AML and MM Patients
University of Pennsylvania
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Cartesian Therapeutics
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
Fred Hutchinson Cancer Center
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Ohio State University Comprehensive Cancer Center
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc.
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
University of Pennsylvania
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
University of Utah
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
RLI
Massachusetts General Hospital
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
University of Alabama at Birmingham
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Indiana University
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center